A detailed history of Price T Rowe Associates Inc transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 1,275,303 shares of REGN stock, worth $911 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares
1,275,303
Previous 932,874 36.71%
Holding current value
$911 Million
Previous $980 Million 36.73%
% of portfolio
0.15%
Previous 0.12%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1024.09 - $1201.76 $351 Million - $412 Million
342,429 Added 36.71%
1,275,303 $1.34 Billion
Q2 2024

Aug 14, 2024

BUY
$883.2 - $1071.19 $26.7 Million - $32.4 Million
30,261 Added 3.35%
932,874 $980 Million
Q1 2024

May 15, 2024

BUY
$902.69 - $993.35 $167 Million - $183 Million
184,561 Added 25.7%
902,613 $869 Million
Q4 2023

Feb 14, 2024

SELL
$775.18 - $881.7 $1.16 Billion - $1.32 Billion
-1,499,613 Reduced 67.62%
718,052 $631 Million
Q3 2023

Nov 14, 2023

SELL
$692.45 - $844.37 $24 Million - $29.2 Million
-34,598 Reduced 1.54%
2,217,665 $1.83 Billion
Q2 2023

Aug 14, 2023

BUY
$700.03 - $830.35 $51.8 Million - $61.5 Million
74,031 Added 3.4%
2,252,263 $1.62 Billion
Q1 2023

May 15, 2023

BUY
$680.49 - $826.97 $309 Million - $376 Million
454,510 Added 26.37%
2,178,232 $1.79 Billion
Q4 2022

Feb 14, 2023

SELL
$705.89 - $766.39 $18.9 Million - $20.6 Million
-26,839 Reduced 1.53%
1,723,722 $1.24 Billion
Q3 2022

Nov 14, 2022

BUY
$573.97 - $724.32 $32.3 Million - $40.7 Million
56,253 Added 3.32%
1,750,561 $1.21 Billion
Q2 2022

Aug 15, 2022

BUY
$548.35 - $738.84 $446 Million - $601 Million
813,967 Added 92.46%
1,694,308 $1 Billion
Q1 2022

May 16, 2022

SELL
$595.12 - $698.43 $19.6 Million - $23 Million
-32,914 Reduced 3.6%
880,341 $615 Million
Q4 2021

Feb 14, 2022

BUY
$543.48 - $670.97 $56.2 Million - $69.4 Million
103,415 Added 12.77%
913,255 $577 Million
Q3 2021

Nov 15, 2021

SELL
$574.03 - $680.96 $8.61 Million - $10.2 Million
-15,004 Reduced 1.82%
809,840 $490 Million
Q2 2021

Aug 16, 2021

SELL
$472.8 - $558.54 $17.9 Million - $21.2 Million
-37,899 Reduced 4.39%
824,844 $461 Million
Q1 2021

May 17, 2021

SELL
$446.73 - $548.2 $2.35 Million - $2.88 Million
-5,256 Reduced 0.61%
862,743 $408 Million
Q4 2020

Feb 16, 2021

BUY
$478.3 - $607.98 $415 Million - $528 Million
867,999 New
867,999 $419 Million

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $76.6B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.